Literature DB >> 12891561

Pain as a complication of use of opiate antagonists for symptom control in cholestasis.

Christine A McRae1, Martin I Prince, Mark Hudson, Christopher P Day, Oliver F W James, David E J Jones.   

Abstract

Controlled trials have suggested that opiate antagonist therapy may be effective for the treatment of the symptoms of cholestasis. The oral opiate antagonist naltrexone in particular has started to enter into routine clinical use for amelioration of cholestatic itch. Attention regarding the side effects of opiate antagonist therapy has, to date, largely focused on an opiate withdrawal-type reaction (which can be controlled effectively by titrated therapy introduction regimens). Here we describe 3 cases of a further clinically important side effect, loss of control of pain resulting from other pathologies, which in each case necessitated the withdrawal of hitherto clinically effective opiate antagonist therapy. Of the 14 patients treated by our unit with opiate antagonist agents for the control of cholestatic symptoms, 13 (93%) showed resolution of, or significant improvement in, symptoms. Of the 13 patients showing a clinical response, 7 (54%) subsequently had to discontinue therapy because of side effects (including the 3 patients with uncontrolled pain). It is our experience that in the routine clinical setting, opiate antagonists are highly effective for the treatment of cholestatic symptoms. In practice, however, their usefulness is limited by their side-effect profile.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12891561     DOI: 10.1016/s0016-5085(03)00879-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  14 in total

Review 1.  [Interactions between itch and pain].

Authors:  M Schmelz
Journal:  Hautarzt       Date:  2006-05       Impact factor: 0.751

2.  A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.

Authors:  Fernanda Q Onofrio; Gideon M Hirschfield; Aliya F Gulamhusein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-03

3.  Ondansetron to treat pruritus due to cholestatic jaundice.

Authors:  Sarah Dillon; Joseph D Tobias
Journal:  J Pediatr Pharmacol Ther       Date:  2013-07

4.  The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Authors:  Gideon M Hirschfield; Jessica K Dyson; Graeme J M Alexander; Michael H Chapman; Jane Collier; Stefan Hübscher; Imran Patanwala; Stephen P Pereira; Collette Thain; Douglas Thorburn; Dina Tiniakos; Martine Walmsley; George Webster; David E J Jones
Journal:  Gut       Date:  2018-03-28       Impact factor: 23.059

Review 5.  Anatomy and neurophysiology of pruritus.

Authors:  Akihiko Ikoma; Ferda Cevikbas; Cordula Kempkes; Martin Steinhoff
Journal:  Semin Cutan Med Surg       Date:  2011-06

Review 6.  Current management of primary sclerosing cholangitis in pediatric patients.

Authors:  Samar H Ibrahim; Keith D Lindor
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 7.  Frontiers in pruritus research: scratching the brain for more effective itch therapy.

Authors:  Ralf Paus; Martin Schmelz; Tamás Bíró; Martin Steinhoff
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

8.  Effect of oral naltrexone on pruritus in cholestatic patients.

Authors:  Fariborz Mansour-Ghanaei; Amir Taheri; Hossein Froutan; Hadi Ghofrani; Mohsen Nasiri-Toosi; Amir-Hossein Bagherzadeh; Mohammad-Jafar Farahvash; Shahram Mirmomen; Naser Ebrahimi-Dariani; Elham Farhangi; Zahra Pourrasouli
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

9.  Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports.

Authors:  Alallam Alallam; David Barth; E Jenny Heathcote
Journal:  Can J Gastroenterol       Date:  2008-05       Impact factor: 3.522

Review 10.  Drug treatment of pruritus in liver diseases.

Authors:  Vinod S Hegade; Stuart F W Kendrick; David E J Jones
Journal:  Clin Med (Lond)       Date:  2015-08       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.